ESR1 and neoplasm: Tumor-associated carbohydrate antigens (TACAs) are broad-spectrum targets, and immunization with carbohydrate mimetic peptides (CMPs) can induce TACA-reactive antibodies to inhibit tumor cell survival.128 One CMP that has made it to clinical trials is P10s which was conjugated to the Pan T-cell carrier PADRE (P10s-PADRE).128 This was given with Montanide ISA 51 VG, a CTL enhancing agent,129 in the adjuvant setting in stage IV BC patients130 (NCT01390064) as well as in the neoadjuvant setting in ER+ patients (NCT02229084) and TNBC patients (NCT02938442).